Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

NCT01868568 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 1

Interventions

DRUG: insulin degludec
DRUG: insulin degludec/insulin aspart 30
DRUG: insulin degludec/insulin aspart 40
DRUG: insulin degludec/insulin aspart 45
DRUG: insulin degludec/insulin aspart 55
DRUG: insulin aspart
DRUG: biphasic insulin aspart 30
DRUG: placebo

Sponsor

Novo Nordisk A/S